AstraZeneca will store your personal data for a number of years in accordance with local laws and the company´s Document Retention Policy. International Transfer AstraZeneca entities and third parties may be based anywhere in the world, which could include countries that may not offer the same...
List of Approved drugs of Astrazeneca Plc listed with Health Canada in the Drug Product Database (DPD)
This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines. We invest in distinctive science in three main therapy areas where we can make the most meaningful difference: oncology; cardiovascular and metabolic disease; and respiratory,...
Astrazeneca PLC Company Information Astrazeneca PLC Company Overview "AstraZeneca develops pharmaceutical solutions for cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation." Astrazeneca PLC Mission, Vision & Values ...
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metab...
“The investment comes after the company disclosed plans for a A$100m ($67.44m) investment in 2017 to increase the production capacity of the plant.” AstraZeneca delivered drug products worth A$500m ($338m) to the domestic market, manufacturing more than 80 different product types of diluen...
Prohost Portfolio PLUS #3 CureVac N.V. We were looking forward to learning more important details about the German firm, CureVac N.V. (CVAC), when the company announced business updates and financial results for its fourth quarter and full-year 2020. The reason for our interest was the fac...
Public Company Incorporated:1999 Employees:50,000 (2000 est.) Sales:US$16.48 billion (2001) Stock Exchanges:New York London Stockholm Ticker Symbol:AZN NAIC:325412 Pharmaceutical Preparation Manufacturing; 325998 All Other Miscellaneous Chemical Product and Preparation Manufacturing; 325131 Inorganic Dye an...
The Company issues its Total Revenue and Core EPS guidance for FY 2024 at CER, based on the average foreign exchange rates through 2023. Total Revenue is expected to increase by a low double-digit to low teens percentage Core EPS is expected to increase by a low double-digit to low teens...
AstraZeneca has entered three deals with biotech companies in a drive to broaden its product pipeline.In one deal,the company will work with U.K.-based Argenta Discovery to identify long-acting muscarinic antagonists and dual-acting muscarinic antagonist-beta2 agonist drug candidates for the ...